JP2000508675A - 新規製剤 - Google Patents
新規製剤Info
- Publication number
- JP2000508675A JP2000508675A JP10525511A JP52551198A JP2000508675A JP 2000508675 A JP2000508675 A JP 2000508675A JP 10525511 A JP10525511 A JP 10525511A JP 52551198 A JP52551198 A JP 52551198A JP 2000508675 A JP2000508675 A JP 2000508675A
- Authority
- JP
- Japan
- Prior art keywords
- budesonide
- unit dose
- dose
- less
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims description 26
- 238000009472 formulation Methods 0.000 title claims description 21
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 40
- 229960004436 budesonide Drugs 0.000 claims abstract description 40
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 208000000592 Nasal Polyps Diseases 0.000 claims description 3
- 206010039094 Rhinitis perennial Diseases 0.000 claims description 3
- 208000036284 Rhinitis seasonal Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 239000012736 aqueous medium Substances 0.000 claims description 3
- 239000007900 aqueous suspension Substances 0.000 claims description 3
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 2
- 208000022719 perennial allergic rhinitis Diseases 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 208000030880 Nose disease Diseases 0.000 abstract description 2
- 208000026344 Nasal disease Diseases 0.000 abstract 1
- 239000000725 suspension Substances 0.000 description 10
- -1 fatty acid esters Chemical class 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.約40μgよりも少ない治療的有効量のブデソニドを含む治療組成物(該組 成物は哺乳類に一回投与で経鼻投与するのに適している)の、定量式単位投与量 。 2.約16から約40μgのブデソニドを含む、請求項1記載の単位投与量。 3.約32μgのブデソニドを含む、請求項1記載の単位投与量。 4.ブデソニドが細砕粒子の形であり、水性媒体に懸濁しているものである、 請求項1から3のいずれかに記載の単位投与量。 5.約0.6から約0.7mg/mlの細砕ブデソニドの水性懸濁液を含む、製剤。 6.更に薬理学的に許容される濃厚剤、等張化剤、界面活性剤、キレート化剤 または防腐剤を含む、請求項1から4のいずれかに記載の単位投与量または請求 項5記載の製剤。 7.ブデソニドの等質量球径が10μmより小さいものである、請求項1から 4および6のいずれかに記載の単位投与量または請求項5または6に記載の製剤 。 8.経鼻投与による、呼吸管上部の病気の処置または予防のための医薬の製造 における、請求項1から7のいずれかに記載の単位投与量または製剤の使用。 9.病気が季節的アレルギー性鼻炎、多年性アレルギー性鼻炎、多年性非アレ ルギー性鼻炎、慢性副鼻腔炎、再発性副鼻腔炎または鼻ポリープである、請求項 8記載の使用。 10.ブデソニドを哺乳類の鼻に1日当たり320μgまたはそれより少ない 量で測り入れ、8回またはそれ以上の単位投与量として投薬し、各単位投与量は 40μgより少ない量の定量式量のブデソニドを含むものである、請求項8また は9に記載の使用。 11.ブデソニドの量が約256μg/日である、請求項10記載の使用。 12.ブデソニドを含み、請求項1から4もしくは6または7のいずれかに記 載の単位投与量または請求項5から7のいずれかに記載の製剤の単位投与量を投 薬するのに適した容器。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9604486A SE9604486D0 (sv) | 1996-12-05 | 1996-12-05 | Novel formulation |
US9604486-2 | 1997-04-29 | ||
US08/846,960 | 1997-04-29 | ||
US08/846,960 US6291445B1 (en) | 1996-12-05 | 1997-04-29 | Low dose budesonide formulations and uses thereof |
PCT/SE1997/001998 WO1998024450A1 (en) | 1996-12-05 | 1997-11-28 | Novel formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000508675A true JP2000508675A (ja) | 2000-07-11 |
JP2000508675A5 JP2000508675A5 (ja) | 2005-03-10 |
Family
ID=26662810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10525511A Ceased JP2000508675A (ja) | 1996-12-05 | 1997-11-28 | 新規製剤 |
Country Status (23)
Country | Link |
---|---|
US (2) | US6686346B2 (ja) |
EP (1) | EP0907365B1 (ja) |
JP (1) | JP2000508675A (ja) |
CN (1) | CN1168450C (ja) |
AT (2) | ATE239482T1 (ja) |
AU (1) | AU726515B2 (ja) |
BE (1) | BE1011394A5 (ja) |
CZ (1) | CZ295792B6 (ja) |
DE (2) | DE69721766T2 (ja) |
DK (1) | DK0907365T3 (ja) |
ES (1) | ES2133130B1 (ja) |
FR (1) | FR2756739B1 (ja) |
GR (1) | GR1003011B (ja) |
HK (1) | HK1020522A1 (ja) |
HU (1) | HUP0000575A3 (ja) |
IE (1) | IE970854A1 (ja) |
IL (1) | IL125534A (ja) |
NL (1) | NL1007706C2 (ja) |
NO (1) | NO983555D0 (ja) |
NZ (1) | NZ330925A (ja) |
PT (1) | PT907365E (ja) |
TR (1) | TR199801501T1 (ja) |
WO (1) | WO1998024450A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006523630A (ja) * | 2003-04-16 | 2006-10-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 鼻用医薬製剤およびその使用方法 |
US8129364B2 (en) | 2003-04-16 | 2012-03-06 | Dey Pharma, L.P. | Formulations and methods for treating rhinosinusitis |
US8158154B2 (en) | 2003-04-16 | 2012-04-17 | Dey Pharma, L.P. | Nasal pharmaceutical formulations and methods of using the same |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2756739B1 (fr) * | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
MY133181A (en) * | 1998-09-10 | 2007-10-31 | Schering Corp | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
AR026073A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
JP2005504090A (ja) | 2001-09-26 | 2005-02-10 | バクスター・インターナショナル・インコーポレイテッド | 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製 |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
US20050026887A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a steroid |
WO2005027853A2 (en) * | 2003-09-19 | 2005-03-31 | University Of Louisville Research Foundation Inc | Method for treating snoring and sleep apnea with leukotriene antagonists |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US20070110788A1 (en) * | 2005-11-14 | 2007-05-17 | Hissong James B | Injectable formulation capable of forming a drug-releasing device |
US7993675B2 (en) | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
US7976873B2 (en) * | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
US7959943B2 (en) * | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
US20070264296A1 (en) * | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
ES2298049B1 (es) * | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
US8088095B2 (en) * | 2007-02-08 | 2012-01-03 | Medtronic Xomed, Inc. | Polymeric sealant for medical use |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
CA2608561A1 (en) * | 2007-10-29 | 2009-04-29 | Carl Paluszkiewicz | Motorcycle wind deflector accessory support |
US20090131386A1 (en) * | 2007-11-13 | 2009-05-21 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
MX349677B (es) | 2007-11-13 | 2017-08-08 | Meritage Pharma Inc | Composiciones corticosteroides. |
US20090123551A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
US20090264392A1 (en) * | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
WO2009152374A2 (en) | 2008-06-12 | 2009-12-17 | Medtronic Xomed, Inc. | Method for treating chronic wounds |
EP2346324A4 (en) | 2008-10-06 | 2012-10-10 | Microbial Defense Systems Llc | ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING |
US20110097401A1 (en) * | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
AU2012253476B2 (en) | 2011-05-10 | 2015-09-24 | Next Science IP Holdings Pty Ltd | Antimicrobial solid and methods of making and using same |
CN112516087B (zh) * | 2020-12-24 | 2023-03-24 | 四川普锐特药业有限公司 | 布地奈德鼻喷剂及其制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE378109B (ja) * | 1972-05-19 | 1975-08-18 | Bofors Ab | |
US3992534A (en) * | 1972-05-19 | 1976-11-16 | Ab Bofors | Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods |
PL164294B1 (pl) * | 1990-12-20 | 1994-07-29 | Inst Farmaceutyczny | Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL |
DE69232462T2 (de) * | 1991-12-18 | 2002-10-10 | Astrazeneca Ab | Formoterol und budesonide enthaltende zusammensetzung |
GB2269992A (en) * | 1992-08-14 | 1994-03-02 | Rh Ne Poulenc Rorer Limited | Powder inhalation formulations |
US5509404A (en) | 1994-07-11 | 1996-04-23 | Aradigm Corporation | Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values |
AU6392496A (en) | 1995-06-29 | 1997-01-30 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
WO1997001341A1 (en) * | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal mast cell stabilizers and topical nasal steroids |
EP0780127A1 (en) * | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
AU3153797A (en) * | 1996-06-04 | 1998-01-05 | Procter & Gamble Company, The | A nasal spray containing an intranasal steroid and an antihistamine |
FR2756739B1 (fr) * | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
SE9604486D0 (sv) * | 1996-12-05 | 1996-12-05 | Astra Ab | Novel formulation |
-
1997
- 1997-11-21 FR FR9714662A patent/FR2756739B1/fr not_active Expired - Fee Related
- 1997-11-27 ES ES009702483A patent/ES2133130B1/es not_active Expired - Fee Related
- 1997-11-28 AT AT97948065T patent/ATE239482T1/de not_active IP Right Cessation
- 1997-11-28 HU HU0000575A patent/HUP0000575A3/hu unknown
- 1997-11-28 CN CNB971920796A patent/CN1168450C/zh not_active Expired - Fee Related
- 1997-11-28 DK DK97948065T patent/DK0907365T3/da active
- 1997-11-28 DE DE69721766T patent/DE69721766T2/de not_active Revoked
- 1997-11-28 EP EP97948065A patent/EP0907365B1/en not_active Revoked
- 1997-11-28 TR TR1998/01501T patent/TR199801501T1/xx unknown
- 1997-11-28 DE DE69738000T patent/DE69738000T2/de not_active Revoked
- 1997-11-28 WO PCT/SE1997/001998 patent/WO1998024450A1/en not_active Application Discontinuation
- 1997-11-28 IL IL12553497A patent/IL125534A/xx not_active IP Right Cessation
- 1997-11-28 NZ NZ330925A patent/NZ330925A/xx unknown
- 1997-11-28 PT PT97948065T patent/PT907365E/pt unknown
- 1997-11-28 JP JP10525511A patent/JP2000508675A/ja not_active Ceased
- 1997-11-28 AU AU54211/98A patent/AU726515B2/en not_active Ceased
- 1997-11-28 CZ CZ19982437A patent/CZ295792B6/cs not_active IP Right Cessation
- 1997-11-28 AT AT02028325T patent/ATE369118T1/de not_active IP Right Cessation
- 1997-12-02 GR GR970100477A patent/GR1003011B/el not_active IP Right Cessation
- 1997-12-02 BE BE9700979A patent/BE1011394A5/fr not_active IP Right Cessation
- 1997-12-03 IE IE970854A patent/IE970854A1/en not_active IP Right Cessation
- 1997-12-05 NL NL1007706A patent/NL1007706C2/nl not_active IP Right Cessation
-
1998
- 1998-08-03 NO NO983555A patent/NO983555D0/no unknown
-
1999
- 1999-10-13 HK HK99104513A patent/HK1020522A1/xx not_active IP Right Cessation
-
2001
- 2001-08-20 US US09/933,974 patent/US6686346B2/en not_active Expired - Fee Related
-
2003
- 2003-11-17 US US10/716,357 patent/US6986904B2/en not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006523630A (ja) * | 2003-04-16 | 2006-10-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 鼻用医薬製剤およびその使用方法 |
JP4680180B2 (ja) * | 2003-04-16 | 2011-05-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 鼻用医薬製剤およびその使用方法 |
US8129364B2 (en) | 2003-04-16 | 2012-03-06 | Dey Pharma, L.P. | Formulations and methods for treating rhinosinusitis |
US8158154B2 (en) | 2003-04-16 | 2012-04-17 | Dey Pharma, L.P. | Nasal pharmaceutical formulations and methods of using the same |
US8309061B2 (en) | 2003-04-16 | 2012-11-13 | Dey Pharma, L.P. | Formulations and methods for treating rhinosinusitis |
US8663695B2 (en) | 2003-04-16 | 2014-03-04 | Mylan Specialty L.P. | Formulations and methods for treating rhinosinusitis |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US9180126B2 (en) | 2003-04-16 | 2015-11-10 | Mylan Specialty L.P. | Formulations and methods for treating rhinosinusitis |
US9808471B2 (en) | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000508675A (ja) | 新規製剤 | |
US6291445B1 (en) | Low dose budesonide formulations and uses thereof | |
RU2327450C2 (ru) | Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды | |
US20090221541A1 (en) | Pharmaceutical formulations | |
FR2651677A1 (fr) | Composition pharmaceutique a base de salmeterol et du propionate de fluticasone. | |
US20110189106A1 (en) | Intranasal compositions, dosage forms and methods of treatment | |
US20090238771A1 (en) | Pharmaceutical formulations | |
US20100144610A1 (en) | Pharmaceutical formulations | |
CN101347436B (zh) | 甲泼尼龙及其衍生物在制备治疗变应性鼻炎的药物中的应用 | |
WO2022143722A1 (zh) | 吸入用药物组合物 | |
US20220370445A1 (en) | Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040603 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080226 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080715 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081021 |